Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Impact of Polycystic Ovary Syndrome (PCOS) on the Risk of Developing Ovarian Cancer and Thyroid Disorders: A Comprehensive Review

Author(s): Payal Mukherjee, Somali Sanyal, Sonia Chadha and Sayali Mukherjee*

Volume 24, Issue 5, 2024

Published on: 17 November, 2023

Page: [562 - 572] Pages: 11

DOI: 10.2174/0118715303266512231103075551

Price: $65

Abstract

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects women. It is characterized by hyperandrogenism, polycystic ovarian morphology, and other related disorders. It is associated with various health conditions, such as infertility and increased risk of heart problems. Ovarian cancer is also a significant concern, as it is the fifth leading cause of death in women. While there is evidence suggesting a potential association between PCOS and ovarian cancer, the exact nature of this relationship remains unclear. Thyroid disorders, particularly hypothyroidism and Hashimoto's thyroiditis, have also been linked to PCOS. The presence of hypothyroidism can contribute to the development of polycystic ovarian morphology, affecting ovulation and hormone balance. Many works have shown a higher ubiquity of autoimmune thyroid disease in PCOS patients, indicating a potential association between the two conditions. The occurrence of PCOS, hirsutism, and acne underscores the frequency of endocrine disorders in women. This review paper examines the present relevant work on the association between PCOS and ovarian cancer as well as PCOS and thyroid disorders. A systematic literature search was conducted on the internet, such as PubMed, Scopus, and Google Scholar database, to identify peer-reviewed publications pertaining to PCOS, ovarian cancer, and thyroid disorders. While some studies have delineated a significant link between PCOS and ovarian cancer or thyroid disorders, others have yielded inconclusive results. Further research is necessary to establish a definitive causal relationship between these conditions. Understanding the relationship between PCOS, ovarian cancer, and thyroid disorders is crucial for early detection, accurate diagnosis, and effective management of these conditions. Identifying potential risk factors and developing appropriate screening strategies can improve women's health outcomes and reduce the burden associated with these disorders.

« Previous Next »
Graphical Abstract

[1]
Azziz, R.; Carmina, E.; Chen, Z.; Dunaif, A.; Laven, J.S.E.; Legro, R.S.; Lizneva, D.; Natterson-Horowtiz, B.; Teede, H.J.; Yildiz, B.O. Polycystic ovary syndrome. Nat. Rev. Dis. Primers, 2016, 2(1), 16057.
[http://dx.doi.org/10.1038/nrdp.2016.57] [PMID: 27510637]
[2]
Leon, LI; Anastasopoulou, C; Mayrin, JV Polycystic Ovarian Disease; StatPearls Publishing: Treasure Island (FL), 2022.
[3]
Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian cancer. Lancet, 2014, 384(9951), 1376-1388.
[http://dx.doi.org/10.1016/S0140-6736(13)62146-7] [PMID: 24767708]
[4]
Kowalczyk, K.; Franik, G.; Kowalczyk, D.; Pluta, D.; Blukacz, Ł.; Madej, P. Thyroid disorders in polycystic ovary syndrome. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(2), 346-360.
[PMID: 28165551]
[5]
Singla, R.; Gupta, Y.; Khemani, M.; Aggarwal, S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J. Endocrinol. Metab., 2015, 19(1), 25-29.
[http://dx.doi.org/10.4103/2230-8210.146860] [PMID: 25593822]
[6]
Zwain, Z.M.; Aziz, M.K. Polycystic ovarian syndrome and thyroid disorders. Intern. J. Techn. Res., 2016, 4, 73-77.
[7]
Azziz, R.; Woods, K.S.; Reyna, R.; Key, T.J.; Knochenhauer, E.S.; Yildiz, B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab., 2004, 89(6), 2745-2749.
[http://dx.doi.org/10.1210/jc.2003-032046] [PMID: 15181052]
[8]
Knochenhauer, E.S.; Key, T.J.; Kahsar-Miller, M.; Waggoner, W.; Boots, L.R.; Azziz, R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J. Clin. Endocrinol. Metab., 1998, 83(9), 3078-3082.
[http://dx.doi.org/10.1210/jc.83.9.3078] [PMID: 9745406]
[9]
Michelmore, K.F.; Balen, A.H.; Dunger, D.B.; Vessey, M.P. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.), 1999, 51(6), 779-786.
[http://dx.doi.org/10.1046/j.1365-2265.1999.00886.x] [PMID: 10619984]
[10]
Clayton, R.N.; Ogden, V.; Hodgkinson, J.; Worswick, L.; Rodin, D.A.; Dyer, S.; Meade, T.W. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin. Endocrinol. (Oxf.), 1992, 37(2), 127-134.
[http://dx.doi.org/10.1111/j.1365-2265.1992.tb02296.x] [PMID: 1395063]
[11]
Roumain, J.; Charles, M.A.; Courten, M.P.D.; Hanson, R.L.; Brodie, T.D.; Pettitt, D.J.; Knowler, W.C. The relationship of menstrual irregularity to type 2 diabetes in Pima Indian women. Diabetes Care, 1998, 21(3), 346-349.
[http://dx.doi.org/10.2337/diacare.21.3.346] [PMID: 9540014]
[12]
Diamanti-Kandarakis, E.; Kouli, C.R.; Bergiele, A.T.; Filandra, F.A.; Tsianateli, T.C.; Spina, G.G.; Zapanti, E.D.; Bartzis, M.I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J. Clin. Endocrinol. Metab., 1999, 84(11), 4006-4011.
[http://dx.doi.org/10.1210/jcem.84.11.6148] [PMID: 10566641]
[13]
Schildkraut, J.; Schwingl, P.J.; Bastos, E.; Evanoff, A.; Hughes, C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol., 1996, 88(4), 554-559.
[http://dx.doi.org/10.1016/0029-7844(96)00226-8] [PMID: 8841217]
[14]
Harris, H.R.; Titus, L.J.; Cramer, D.W.; Terry, K.L. Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study. Int. J. Cancer, 2017, 140(2), 285-291.
[http://dx.doi.org/10.1002/ijc.30441] [PMID: 27667654]
[15]
Harris, H.R.; Babic, A.; Webb, P.M.; Nagle, C.M.; Jordan, S.J.; Risch, H.A.; Rossing, M.A.; Doherty, J.A.; Goodman, M.T.; Modugno, F.; Ness, R.B.; Moysich, K.B.; Kjær, S.K.; Høgdall, E.; Jensen, A.; Schildkraut, J.M.; Berchuck, A.; Cramer, D.W.; Bandera, E.V.; Wentzensen, N.; Kotsopoulos, J.; Narod, S.A.; Phelan, C.M.; McLaughlin, J.R.; Anton-Culver, H.; Ziogas, A.; Pearce, C.L.; Wu, A.H.; Terry, K.L. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev., 2018, 27(2), 174-182.
[http://dx.doi.org/10.1158/1055-9965.EPI-17-0655] [PMID: 29141849]
[16]
Harris, H.R.; Terry, K.L. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertil. Res. Pract., 2016, 2(1), 14.
[http://dx.doi.org/10.1186/s40738-016-0029-2] [PMID: 28620541]
[17]
Harris, H.R.; Cushing-Haugen, K.L.; Webb, P.M.; Nagle, C.M.; Jordan, S.J.; Risch, H.A.; Rossing, M.A.; Doherty, J.A.; Goodman, M.T.; Modugno, F.; Ness, R.B.; Moysich, K.B.; Kjær, S.K.; Høgdall, E.; Jensen, A.; Schildkraut, J.M.; Berchuck, A.; Cramer, D.W.; Bandera, E.V.; Rodriguez, L.; Wentzensen, N.; Kotsopoulos, J.; Narod, S.A.; McLaughlin, J.R.; Anton-Culver, H.; Ziogas, A.; Pearce, C.L.; Wu, A.H.; Lindström, S.; Terry, K.L. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: A Mendelian randomization study. Int. J. Epidemiol., 2019, 48(3), 822-830.
[http://dx.doi.org/10.1093/ije/dyz113] [PMID: 31211375]
[18]
Shen, C.C.; Yang, A.C.; Hung, J.H.; Hu, L.Y.; Tsai, S.J. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist, 2015, 20(1), 45-49.
[http://dx.doi.org/10.1634/theoncologist.2014-0311] [PMID: 25410097]
[19]
Barry, J.A.; Azizia, M.M.; Hardiman, P.J. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. Update, 2014, 20(5), 748-758.
[http://dx.doi.org/10.1093/humupd/dmu012] [PMID: 24688118]
[20]
Amiri, M; Bidhendi-Yarandi, R; Fallahzadeh, A; Marzban, Z; Tehrani, FR >Risk of endometrial, ovarian, and breast cancers in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod Biomed, 2022, 20(11), 893-914.
[http://dx.doi.org/10.18502/ijrm.v20i11.12357]
[21]
Romitti, M.; Fabris, V.C.; Ziegelmann, P.K.; Maia, A.L.; Spritzer, P.M. Association between PCOS and autoimmune thyroid disease: A systematic review and meta-analysis. Endocr. Connect., 2018, 7(11), 1158-1167.
[http://dx.doi.org/10.1530/EC-18-0309] [PMID: 30352422]
[22]
Ding, X.; Yang, L.; Wang, J.; Tang, R.; Chen, Q.; Pan, J.; Yang, H.; Chen, X.; Chen, Z.; Mu, L. Subclinical hypothyroidism in polycystic ovary syndrome: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne), 2018, 9, 700.
[http://dx.doi.org/10.3389/fendo.2018.00700] [PMID: 30542323]
[23]
Kim, J.J.; Yoon, J.W.; Kim, M.J.; Kim, S.M.; Hwang, K.R.; Choi, Y.M. Thyroid autoimmunity markers in women with polycystic ovary syndrome and controls. Hum. Fertil. (Camb.), 2022, 25(1), 128-134.
[http://dx.doi.org/10.1080/14647273.2019.1709668] [PMID: 31910041]
[24]
Kalra, S.; Aggarwal, S.; Khandelwal, D. Thyroid dysfunction and dysmetabolic syndrome: The need for enhanced thyrovigilance strategies. Int. J. Endocrinol., 2021, 2021, 1-11.
[http://dx.doi.org/10.1155/2021/9641846] [PMID: 33859689]
[25]
Ho, C.W.; Chen, H.H.; Hsieh, M.C.; Chen, C.C.; Hsu, S.P.; Yip, H.T.; Kao, C.H. Increased risk of polycystic ovary syndrome and It’s comorbidities in women with autoimmune thyroid disease. Int. J. Environ. Res. Public Health, 2020, 17(7), 2422.
[http://dx.doi.org/10.3390/ijerph17072422] [PMID: 32252386]
[26]
Arduc, A.; Aycicek Dogan, B.; Bilmez, S.; Imga Nasiroglu, N.; Tuna, M.M.; Isik, S.; Berker, D.; Guler, S. High prevalence of Hashimoto’s thyroiditis in patients with polycystic ovary syndrome: Does the imbalance between estradiol and progesterone play a role? Endocr. Res., 2015, 40(4), 204-210.
[http://dx.doi.org/10.3109/07435800.2015.1015730] [PMID: 25822940]
[27]
Arora, S.; Sinha, K.; Kolte, S.; Mandal, A. Endocrinal and autoimmune linkage: Evidences from a controlled study of subjects with polycystic ovarian syndrome. J. Hum. Reprod. Sci., 2016, 9(1), 18-22.
[http://dx.doi.org/10.4103/0974-1208.178636] [PMID: 27110073]
[28]
Petrikova, J.; Lazurova, I.; Dravecka, I.; Vrbikova, J.; Kozakova, D.; Figurova, J.; Vaczy, Z.; Rosocha, J. The prevalence of non organ specific and thyroid autoimmunity in patients with polycystic ovary syndrome. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2015, 159(2), 302-306.
[http://dx.doi.org/10.5507/bp.2014.062] [PMID: 25485530]
[29]
Anwaar, M.; Jabeen, Q.
[30]
Ganie, M.A.; Marwaha, R.K.; Aggarwal, R.; Singh, S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: A case–control study. Eur. J. Endocrinol., 2010, 162(6), 1117-1122.
[http://dx.doi.org/10.1530/EJE-09-1012] [PMID: 20332127]
[31]
Garelli, S.; Masiero, S.; Plebani, M.; Chen, S.; Furmaniak, J.; Armanini, D.; Betterle, C. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 169(2), 248-251.
[http://dx.doi.org/10.1016/j.ejogrb.2013.03.003] [PMID: 23548659]
[32]
Kisielewski, R.; Mazurek, A.; Laudański, P.; Tołwińska, A. Inflammation and ovarian cancer - current views. Ginekol. Pol., 2013, 84(4), 293-297.
[http://dx.doi.org/10.17772/gp/1579] [PMID: 23700863]
[33]
Ting, S; Tiedje, V; Badziong, J; Selich, O; Sheu, SY; Moeller, LC; Weber, J; Schmid, KW; Brix, K; Führer, D; Zwanziger, D MCT 8 and LAT 2 expression in differentially functioning benign and malignant thyroid tumors. Exp. Clin. Endocrino. Diabetes, 2014, 122(3)
[http://dx.doi.org/10.1055/s-0034-1372099]
[34]
Lee, H.J.; Bahr, J.M.; Bitterman, P.; Basu, S.; Sharma, S.; Abramowicz, J.S.; Barua, A. Polycystic ovarian condition may be a risk factor for ovarian tumor development in the laying hen model of spontaneous ovarian cancer. J. Immunol. Res., 2018, 2018, 1-13.
[http://dx.doi.org/10.1155/2018/2590910] [PMID: 30596106]
[35]
Harrington, B.S.; Annunziata, C.M. NF-κB signaling in ovarian cancer. Cancers (Basel), 2019, 11(8), 1182.
[http://dx.doi.org/10.3390/cancers11081182] [PMID: 31443240]
[36]
Zuo, T; Zhu, M; Xu, W Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev., 2016, 2016, 8589318.
[http://dx.doi.org/10.1155/2016/8589318]
[37]
Ott, J.; Aust, S.; Kurz, C.; Nouri, K.; Wirth, S.; Huber, J.C.; Mayerhofer, K. Elevated antithyroid peroxidase antibodies indicating Hashimoto’s thyroiditis are associated with the treatment response in infertile women with polycystic ovary syndrome. Fertil. Steril., 2010, 94(7), 2895-2897.
[http://dx.doi.org/10.1016/j.fertnstert.2010.05.063] [PMID: 20638057]
[38]
De Leo, V.; Musacchio, M.C.; Cappelli, V.; Massaro, M.G.; Morgante, G.; Petraglia, F. Genetic, hormonal and metabolic aspects of PCOS: An update. Reprod. Biol. Endocrinol., 2016, 14(1), 38.
[http://dx.doi.org/10.1186/s12958-016-0173-x] [PMID: 27423183]
[39]
Sikiru, A.B.; Adeniran, M.A.; Akinola, K.; Behera, H.; Kalaignazhal, G.; Egena, S.S.A. Unraveling the complexity of the molecular pathways associated with polycystic ovary syndrome (PCOS) and identifying molecular targets for therapeutic development: A review of literature. Middle East Fertil. Soc. J., 2023, 28(1), 16.
[http://dx.doi.org/10.1186/s43043-023-00142-w]
[40]
Singh, S.; Pal, N.; Shubham, S.; Sarma, D.K.; Verma, V.; Marotta, F.; Kumar, M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J. Clin. Med., 2023, 12(4), 1454.
[http://dx.doi.org/10.3390/jcm12041454] [PMID: 36835989]
[41]
Abraham Gnanadass, S.; Divakar Prabhu, Y.; Valsala Gopalakrishnan, A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): An update. Arch. Gynecol. Obstet., 2021, 303(3), 631-643.
[http://dx.doi.org/10.1007/s00404-020-05951-2] [PMID: 33439300]
[42]
Patel, S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J. Steroid Biochem. Mol. Biol., 2018, 182, 27-36.
[http://dx.doi.org/10.1016/j.jsbmb.2018.04.008] [PMID: 29678491]
[43]
Rostamtabar, M.; Esmaeilzadeh, S.; Tourani, M.; Rahmani, A.; Baee, M.; Shirafkan, F.; Saleki, K.; Mirzababayi, S.S.; Ebrahimpour, S.; Nouri, H.R. Pathophysiological roles of chronic lowgrade inflammation mediators in polycystic ovary syndrome. J. Cell. Physiol., 2021, 236(2), 824-838.
[http://dx.doi.org/10.1002/jcp.29912] [PMID: 32617971]
[44]
Pawelczak, M.; Rosenthal, J.; Milla, S.; Liu, Y.H.; Shah, B. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol., 2014, 27(6), 356-359.
[http://dx.doi.org/10.1016/j.jpag.2014.01.104] [PMID: 25256873]
[45]
González, F. Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids, 2012, 77(4), 300-305.
[http://dx.doi.org/10.1016/j.steroids.2011.12.003] [PMID: 22178787]
[46]
Johnson, C.E.; Alberg, A.J.; Bandera, E.V.; Peres, L.C.; Akonde, M.; Collin, L.J.; Cote, M.L.; Hastert, T.A.; Hébert, J.R.; Peters, E.S.; Qin, B.; Terry, P.; Schwartz, A.G.; Bondy, M.; Epstein, M.P.; Mandle, H.B.; Marks, J.R.; Lawson, A.B.; Schildkraut, J.M. Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women. Br. J. Cancer, 2023, 129(7), 1119-1125.
[http://dx.doi.org/10.1038/s41416-023-02385-w] [PMID: 37537254]
[47]
McSorley, M.A.; Alberg, A.J.; Allen, D.S.; Allen, N.E.; Brinton, L.A.; Dorgan, J.F.; Pollak, M.; Tao, Y.; Helzlsouer, K.J. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet. Gynecol., 2007, 109(4), 933-941.
[http://dx.doi.org/10.1097/01.AOG.0000257126.68803.03] [PMID: 17400857]
[48]
Lundin, E.; Dossus, L.; Clendenen, T.; Krogh, V.; Grankvist, K.; Wulff, M.; Sieri, S.; Arslan, A.A.; Lenner, P.; Berrino, F.; Hallmans, G.; Zeleniuch-Jacquotte, A.; Toniolo, P.; Lukanova, A. Creactive protein and ovarian cancer: A prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control, 2009, 20(7), 1151-1159.
[http://dx.doi.org/10.1007/s10552-009-9330-2] [PMID: 19301134]
[49]
Soave, I.; Occhiali, T.; Assorgi, C.; Marci, R.; Caserta, D. Environmental toxin exposure in polycystic ovary syndrome women and possible ovarian neoplastic repercussion. Curr. Med. Res. Opin., 2020, 36(4), 693-703.
[http://dx.doi.org/10.1080/03007995.2020.1729108] [PMID: 32046531]
[50]
Sit, M.; Aktas, G.; Ozer, B.; Kocak, M.Z.; Erkus, E.; Erkol, H.; Yaman, S.; Savli, H. Mean platelet volume: An overlooked herald of malignant thyroid nodules. Acta Clin. Croat., 2019, 58(3), 417-420.
[http://dx.doi.org/10.20471/acc.2019.58.03.03] [PMID: 31969752]
[51]
Atak Tel, B.M.; Kahveci, G.; Bilgin, S.; Kurtkulagi, O.; Kosekli, M.A. Platelet to lymphocyte ratio in differentiation of benign and malignant thyroid nodules. Exp. Biomed. Res., 2021, 4(2), 148-153.
[http://dx.doi.org/10.30714/j-ebr.2021267978]
[52]
Jin, J. Screening for ovarian cancer. JAMA, 2018, 319(6), 624.
[http://dx.doi.org/10.1001/jama.2017.22136] [PMID: 29450526]
[53]
PDQ screening and prevention editorial board. Ovarian, fallopian tube, and primary peritoneal cancers screening (PDQ®)PDQ Cancer Information Summaries; Nat. Lib. Med.: Rockville Pike, 2022.
[54]
Chen, A.Y.; Bernet, V.J.; Carty, S.E.; Davies, T.F.; Ganly, I.; Inabnet, W.B., III; Shaha, A.R. american thyroid association statement on optimal surgical management of goiter. Thyroid, 2014, 24(2), 181-189.
[http://dx.doi.org/10.1089/thy.2013.0291] [PMID: 24295043]
[55]
Yu, Q.; Wang, JB Subclinical hypothyroidism in PCOS: Impact on presentation, insulin resistance, and cardiovascular risk. Biomed. Res. Int., 2016, 2016, 2067087.
[http://dx.doi.org/10.1155/2016/2067087]
[56]
Aktas, G.; Sit, M.; Dikbas, O.; Tekce, B.; Savli, H.; Tekçe, H.; Alçelik, A. Could red cell distribution width be a marker in Hashimoto’s thyroiditis? Exp. Clin. Endocrinol. Diabetes, 2014, 122(10), 572-574.
[http://dx.doi.org/10.1055/s-0034-1383564] [PMID: 25380549]
[57]
Bilgin, S.; Tel, B.M.A.; Kahveci, G.; Duman, T.T.; Kurtkulagi, O.; Yurum, S.; Erturk, A.; Balci, B.; Aktas, G. Hypothyroidism is strongly correlated with mean platelet volume and red cell distribution width. Nat. J. Health Sci., 2021, 6(1), 7-10.
[http://dx.doi.org/10.21089/njhs.61.0007]
[58]
Sinha, U.; Sinharay, K.; Saha, S.; Longkumer, T.A.; Baul, S.; Pal, S. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian J. Endocrinol. Metab., 2013, 17(2), 304-309.
[http://dx.doi.org/10.4103/2230-8210.109714] [PMID: 23776908]
[59]
Benetti-Pinto, C.L.; Berini Piccolo, V.R.S.; Garmes, H.M.; Teatin Juliato, C.R. Subclinical hypothyroidism in young women with polycystic ovary syndrome: An analysis of clinical, hormonal, and metabolic parameters. Fertil. Steril., 2013, 99(2), 588-592.
[http://dx.doi.org/10.1016/j.fertnstert.2012.10.006] [PMID: 23103018]
[60]
Muderris, I.I.; Boztosun, A.; Oner, G.; Bayram, F. Effect of thyroid hormone replacement therapy on ovarian volume and androgen hormones in patients with untreated primary hypothyroidism. Ann. Saudi Med., 2011, 31(2), 145-151.
[http://dx.doi.org/10.4103/0256-4947.77500] [PMID: 21403408]
[61]
Armanini, D.; Bordin, L.; Donà, G.; Sabbadin, C.; Bakdounes, L.; Ragazzi, E.; Giorgino, F.L.; Fiore, C. Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids, 2012, 77(6), 655-658.
[http://dx.doi.org/10.1016/j.steroids.2012.02.010] [PMID: 22387621]
[62]
Palomba, S.; Falbo, A.; Chiossi, G.; Muscogiuri, G.; Fornaciari, E.; Orio, F.; Tolino, A.; Colao, A.; La Sala, G.B.; Zullo, F. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study. Steroids, 2014, 88, 36-43.
[http://dx.doi.org/10.1016/j.steroids.2014.06.005] [PMID: 24945113]
[63]
Legro, R.S.; Arslanian, S.A.; Ehrmann, D.A.; Hoeger, K.M.; Murad, M.H.; Pasquali, R.; Welt, C.K. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2013, 98(12), 4565-4592.
[http://dx.doi.org/10.1210/jc.2013-2350] [PMID: 24151290]
[64]
Dietz de Loos, A.; Jiskoot, G.; Beerthuizen, A.; Busschbach, J.; Laven, J. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. Eur. J. Endocrinol., 2022, 186(1), 53-64.
[http://dx.doi.org/10.1530/EJE-21-0669] [PMID: 34714771]
[65]
Cignarella, A.; Mioni, R.; Sabbadin, C.; Dassie, F.; Parolin, M.; Vettor, R.; Barbot, M.; Scaroni, C. Pharmacological approaches to controlling cardiometabolic risk in women with PCOS. Int. J. Mol. Sci., 2020, 21(24), 9554.
[http://dx.doi.org/10.3390/ijms21249554] [PMID: 33334002]
[66]
Dinicola, S.; Unfer, V.; Facchinetti, F.; Soulage, C.O.; Greene, N.D.; Bizzarri, M.; Laganà, A.S.; Chan, S.Y.; Bevilacqua, A.; Pkhaladze, L.; Benvenga, S.; Stringaro, A.; Barbaro, D.; Appetecchia, M.; Aragona, C.; Bezerra Espinola, M.S.; Cantelmi, T.; Cavalli, P.; Chiu, T.T.; Copp, A.J.; D’Anna, R.; Dewailly, D.; Di Lorenzo, C.; Diamanti-Kandarakis, E.; Hernández Marín, I.; Hod, M.; Kamenov, Z.; Kandaraki, E.; Monastra, G.; Montanino Oliva, M.; Nestler, J.E.; Nordio, M.; Ozay, A.C.; Papalou, O.; Porcaro, G.; Prapas, N.; Roseff, S.; Vazquez-Levin, M.; Vucenik, I.; Wdowiak, A. Inositols: From established knowledge to novel approaches. Int. J. Mol. Sci., 2021, 22(19), 10575.
[http://dx.doi.org/10.3390/ijms221910575] [PMID: 34638926]
[67]
Donà, G.; Sabbadin, C.; Fiore, C.; Bragadin, M.; Giorgino, F.L.; Ragazzi, E.; Clari, G.; Bordin, L.; Armanini, D. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol., 2012, 166(4), 703-710.
[http://dx.doi.org/10.1530/EJE-11-0840] [PMID: 22223702]
[68]
Siamashvili, M.; Davis, S.N. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev. Clin. Pharmacol., 2021, 14(9), 1081-1089.
[http://dx.doi.org/10.1080/17512433.2021.1933433] [PMID: 34015974]
[69]
Tentolouris, A.; Vlachakis, P.; Tzeravini, E.; Eleftheriadou, I.; Tentolouris, N. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int. J. Environ. Res. Public Health, 2019, 16(16), 2965.
[http://dx.doi.org/10.3390/ijerph16162965] [PMID: 31426529]
[70]
Bastianelli, C.; Farris, M.; Rosato, E.; Brosens, I.; Benagiano, G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev. Clin. Pharmacol., 2017, 10(3), 315-326.
[PMID: 27977304]
[71]
Grandi, G.; Napolitano, A.; Cagnacci, A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin. Drug Metab. Toxicol., 2016, 12(7), 779-787.
[http://dx.doi.org/10.1080/17425255.2016.1190832] [PMID: 27187588]
[72]
Armanini, D.; Boscaro, M.; Bordin, L.; Sabbadin, C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int. J. Mol. Sci., 2022, 23(8), 4110.
[http://dx.doi.org/10.3390/ijms23084110] [PMID: 35456928]
[73]
Giudice, L.C. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract. Res. Clin. Endocrinol. Metab., 2006, 20(2), 235-244.
[http://dx.doi.org/10.1016/j.beem.2006.03.005] [PMID: 16772154]
[74]
Chittenden, B.G.; Fullerton, G.; Maheshwari, A.; Bhattacharya, S. Polycystic ovary syndrome and the risk of gynaecological cancer: A systematic review. Reprod. Biomed. Online, 2009, 19(3), 398-405.
[http://dx.doi.org/10.1016/S1472-6483(10)60175-7] [PMID: 19778486]
[75]
Niwa, K.; Imai, A.; Hashimoto, M.; Yokoyama, Y.; Mori, H.; Matsuda, Y.; Tamaya, T. A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol. Rep., 2000, 7(1), 89-93.
[http://dx.doi.org/10.3892/or.7.1.89] [PMID: 10601598]
[76]
Baron, J.A.; Weiderpass, E.; Newcomb, P.A.; Stampfer, M.; Titus-Ernstoff, L.; Egan, K.M.; Greenberg, E.R. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control, 2001, 12(10), 875-880.
[http://dx.doi.org/10.1023/A:1013796112348] [PMID: 11808705]
[77]
Gammon, M.D.; Thompson, W.D. Polycystic ovaries and the risk of breast cancer. Am. J. Epidemiol., 1991, 134(8), 818-824.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a116156] [PMID: 1951277]
[78]
Fanta, M. Is polycystic ovary syndrome, a state of relative estrogen excess, a real risk factor for estrogen-dependant malignancies? Gynecol. Endocrinol., 2013, 29(2), 145-147.
[http://dx.doi.org/10.3109/09513590.2012.730575] [PMID: 23127146]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy